世界のアルブミン(賦形剤)市場2022ー2031:製品タイプ別(ヒト血清アルブミン、組換えアルブミン)、用途別(ヒト血清アルブミン、組換えアルブミン)

【英語タイトル】Albumin (as Excipient) Market (Product Type: Human Serum Albumin and Recombinant Albumin; and Application: Human Serum Albumin and Recombinant Albumin) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Transparency Market Researchが出版した調査資料(TMR22AU0069)・商品コード:TMR22AU0069
・発行会社(調査会社):Transparency Market Research
・発行日:2022年6月
・ページ数:200
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,795 ⇒換算¥811,300見積依頼/購入/質問フォーム
Multi User(5名様閲覧)USD8,795 ⇒換算¥1,231,300見積依頼/購入/質問フォーム
Corporate License(法人閲覧)USD11,795 ⇒換算¥1,651,300見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
Transparency Market Research社の当調査資料では、世界のアルブミン(賦形剤)市場について広く調査・分析を行い、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、市場見通し、製品タイプ別(ヒト血清アルブミン、組換えアルブミン)分析、用途別分析、エンドユーザー別分析、地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)分析、競争状況などをまとめました。なお、当書に掲載されている企業情報には、Albumedix Ltd.、Albumin Therapeutics, LLC (Albumin Bioscience)、Biotest AG、CSL Behring (CSL)、Grifols, S.A.、HiMedia Laboratories、InVitria、Medxbio Pte Ltd.、Octapharma AGなどが含まれています。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・市場見通し
・世界のアルブミン(賦形剤)市場規模:製品タイプ別(ヒト血清アルブミン、組換えアルブミン)
・世界のアルブミン(賦形剤)市場規模:用途別
・世界のアルブミン(賦形剤)市場規模:エンドユーザー別
・世界のアルブミン(賦形剤)市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)
・競争状況
❖ レポートの概要 ❖

Albumin (as Excipient) Market – Scope of Report

TMR’s report on the global albumin (as excipient) market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global albumin (as excipient) market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global albumin (as excipient) market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the albumin (as excipient) market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global albumin (as excipient) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global albumin (as excipient) market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global albumin (as excipient) market.

The report delves into the competitive landscape of the global albumin (as excipient) market. Key players operating in the global albumin (as excipient) market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global albumin (as excipient) market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market albumin (as excipient).

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

❖ レポートの目次 ❖

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Global Albumin (as Excipient) Market Forecast
4.4. Global Albumin (as Excipient) Market Outlook
5. Market Outlook
5.1. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
5.2. Technological Advancement
5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Albumin (as Excipient) Market Analysis and Forecast, by Product Type
6.1. Global Albumin (as Excipient) Market Analysis and Forecast, by Product Type
6.2. Introduction
6.3. Global Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Product Type
6.4. Global Albumin (as Excipient) Market Forecast, by Product Type
6.4.1. Human Serum Albumin
6.4.2. Recombinant Albumin
6.5. Global Albumin (as Excipient) Market Analysis, by Product Type
7. Global Albumin (as Excipient) Market Analysis and Forecast, by Application
7.1. Introduction
7.2. Global Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Application
7.3. Global Albumin (as Excipient) Market Forecast, by Application
7.3.1. Human Serum Albumin Applications
7.3.1.1. Drug Formulation
7.3.1.2. Drug Delivery
7.3.1.3. Vaccines
7.3.1.4. Medical Device Coating
7.3.1.5. Culture Medium & Stabilizer
7.3.1.6. Diagnostics
7.3.1.7. In Vitro Fertilization
7.3.2. Recombinant Albumin
7.3.2.1. Drug Formulation
7.3.2.2. Drug Delivery
7.3.2.3. Vaccines
7.3.2.4. Medical Device Coating
7.3.2.5. Culture Medium & Stabilizer
7.3.2.6. Diagnostics
7.3.2.7. In Vitro Fertilization
7.4. Global Albumin (as Excipient) Market Analysis, by Application
8. Global Albumin (as Excipient) Market Analysis and Forecast, by End-user
8.1. Introduction
8.2. Global Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by End-user
8.3. Global Albumin (as Excipient) Market Forecast, by End-user
8.3.1. Pharmaceutical & Biotechnology Industry
8.3.2. Research Institutes
8.3.3. Others
8.4. Global Albumin (as Excipient) Market Analysis, by End-user
9. Global Albumin (as Excipient) Market Analysis and Forecast, by Region
9.1. Global Albumin (as Excipient) Market Analysis, by Region
9.2. Global Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Region
9.3. Global Albumin (as Excipient) Market Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
10. North America Albumin (as Excipient) Market Analysis
10.1. North America Albumin (as Excipient) Market Overview
10.2. North America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Country
10.3. North America Albumin (as Excipient) Market Forecast, by Country
10.3.1. U.S.
10.3.2. Canada
10.4. North America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Product Type
10.5. North America Albumin (as Excipient) Market Forecast, by Product Type
10.5.1. Human Serum Albumin
10.5.2. Recombinant Albumin
10.6. North America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Application
10.7. North America Albumin (as Excipient) Market Forecast, by Application
10.7.1. Human Serum Albumin Applications
10.7.1.1. Drug Formulation
10.7.1.2. Drug Delivery
10.7.1.3. Vaccines
10.7.1.4. Medical Device Coating
10.7.1.5. Culture Medium & Stabilizer
10.7.1.6. Diagnostics
10.7.1.7. In Vitro Fertilization
10.7.2. Recombinant Albumin
10.7.2.1. Drug Formulation
10.7.2.2. Drug Delivery
10.7.2.3. Vaccines
10.7.2.4. Medical Device Coating
10.7.2.5. Culture Medium & Stabilizer
10.7.2.6. Diagnostics
10.7.2.7. In Vitro Fertilization
10.8. North America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by End-user
10.9. North America Albumin (as Excipient) Market Forecast, by End-user
10.9.1. Pharmaceutical & Biotechnology Industry
10.9.2. Research Institutes
10.9.3. Others
11. Europe Albumin (as Excipient) Market Analysis
11.1. Europe Albumin (as Excipient) Market Overview
11.2. Europe Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Countries/Sub-region
11.3. Europe Albumin (as Excipient) Market Forecast, by Countries/Sub-region
11.3.1. Germany
11.3.2. France
11.3.3. U.K.
11.3.4. Italy
11.3.5. Spain
11.3.6. Rest of Europe
11.4. Europe Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Product Type
11.5. Europe Albumin (as Excipient) Market Forecast, by Product Type
11.5.1. Human Serum Albumin
11.5.2. Recombinant Albumin
11.6. Europe Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Application
11.7. Europe Albumin (as Excipient) Market Forecast, by Application
11.7.1. Human Serum Albumin Applications
11.7.1.1. Drug Formulation
11.7.1.2. Drug Delivery
11.7.1.3. Vaccines
11.7.1.4. Medical Device Coating
11.7.1.5. Culture Medium & Stabilizer
11.7.1.6. Diagnostics
11.7.1.7. In Vitro Fertilization
11.7.2. Recombinant Albumin
11.7.2.1. Drug Formulation
11.7.2.2. Drug Delivery
11.7.2.3. Vaccines
11.7.2.4. Medical Device Coating
11.7.2.5. Culture Medium & Stabilizer
11.7.2.6. Diagnostics
11.7.2.7. In Vitro Fertilization
11.8. Europe Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by End-user
11.9. Europe Albumin (as Excipient) Market Forecast, by End-user
11.9.1. Pharmaceutical & Biotechnology Industry
11.9.2. Research Institutes
11.9.3. Others
12. Asia Pacific Albumin (as Excipient) Market Analysis
12.1. Asia Pacific Albumin (as Excipient) Market Overview
12.2. Asia Pacific Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Countries/Sub-region
12.3. Asia Pacific Albumin (as Excipient) Market Forecast, by Countries/Sub-region
12.3.1. Japan
12.3.2. China
12.3.3. India
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Asia Pacific Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Product Type
12.5. Asia Pacific Albumin (as Excipient) Market Forecast, by Product Type
12.5.1. Human Serum Albumin
12.5.2. Recombinant Albumin
12.6. Asia Pacific Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Application
12.7. Asia Pacific Albumin (as Excipient) Market Forecast, by Application
12.7.1. Human Serum Albumin Applications
12.7.1.1. Drug Formulation
12.7.1.2. Drug Delivery
12.7.1.3. Vaccines
12.7.1.4. Medical Device Coating
12.7.1.5. Culture Medium & Stabilizer
12.7.1.6. Diagnostics
12.7.1.7. In Vitro Fertilization
12.7.2. Recombinant Albumin
12.7.2.1. Drug Formulation
12.7.2.2. Drug Delivery
12.7.2.3. Vaccines
12.7.2.4. Medical Device Coating
12.7.2.5. Culture Medium & Stabilizer
12.7.2.6. Diagnostics
12.7.2.7. In Vitro Fertilization
12.8. Asia Pacific Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by End-user
12.9. Asia Pacific Albumin (as Excipient) Market Forecast, by End-user
12.9.1. Pharmaceutical & Biotechnology Industry
12.9.2. Research Institutes
12.9.3. Others
13. Latin America Albumin (as Excipient) Market Analysis
13.1. Latin America Albumin (as Excipient) Market Overview
13.2. Latin America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Countries/Sub-region
13.3. Latin America Albumin (as Excipient) Market Forecast, by Countries/Sub-region
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Latin America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Product Type
13.5. Latin America Albumin (as Excipient) Market Forecast, by Product Type
13.5.1. Human Serum Albumin
13.5.2. Recombinant Albumin
13.6. Latin America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Application
13.7. Latin America Albumin (as Excipient) Market Forecast, by Application
13.7.1. Human Serum Albumin Applications
13.7.1.1. Drug Formulation
13.7.1.2. Drug Delivery
13.7.1.3. Vaccines
13.7.1.4. Medical Device Coating
13.7.1.5. Culture Medium & Stabilizer
13.7.1.6. Diagnostics
13.7.1.7. In Vitro Fertilization
13.7.2. Recombinant Albumin
13.7.2.1. Drug Formulation
13.7.2.2. Drug Delivery
13.7.2.3. Vaccines
13.7.2.4. Medical Device Coating
13.7.2.5. Culture Medium & Stabilizer
13.7.2.6. Diagnostics
13.7.2.7. In Vitro Fertilization
13.8. Latin America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by End-user
13.9. Latin America Albumin (as Excipient) Market Forecast, by End-user
13.9.1. Pharmaceutical & Biotechnology Industry
13.9.2. Research Institutes
13.9.3. Others
14. Middle East & Africa Albumin (as Excipient) Market Analysis
14.1. Middle East & Africa Albumin (as Excipient) Market Overview
14.2. Middle East & Africa Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Countries/Sub-region
14.3. Middle East & Africa Albumin (as Excipient) Market Forecast, by Countries/Sub-region
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of MEA
14.4. Middle East & Africa Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Product Type
14.5. Middle East & Africa Albumin (as Excipient) Market Forecast, by Product Type
14.5.1. Human Serum Albumin
14.5.2. Recombinant Albumin
14.6. Middle East & Africa Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Application
14.7. Middle East & Africa Albumin (as Excipient) Market Forecast, by Application
14.7.1. Human Serum Albumin Applications
14.7.1.1. Drug Formulation
14.7.1.2. Drug Delivery
14.7.1.3. Vaccines
14.7.1.4. Medical Device Coating
14.7.1.5. Culture Medium & Stabilizer
14.7.1.6. Diagnostics
14.7.1.7. In Vitro Fertilization
14.7.2. Recombinant Albumin
14.7.2.1. Drug Formulation
14.7.2.2. Drug Delivery
14.7.2.3. Vaccines
14.7.2.4. Medical Device Coating
14.7.2.5. Culture Medium & Stabilizer
14.7.2.6. Diagnostics
14.7.2.7. In Vitro Fertilization
14.8. Middle East & Africa Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by End-user
14.9. Middle East & Africa Albumin (as Excipient) Market Forecast, by End-user
14.9.1. Pharmaceutical & Biotechnology Industry
14.9.2. Research Institutes
14.9.3. Others
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis/Ranking, by Company, 2021
15.3. Company Profiles
15.3.1. Albumedix Ltd.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Albumin Therapeutics, LLC (Albumin Bioscience)
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Biotest AG
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. CSL Behring (CSL)
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Grifols, S.A.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. HiMedia Laboratories
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. InVitria
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Medxbio Pte Ltd
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Octapharma AG
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. RayBiotech, Inc.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. SeraCare Life Sciences
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. Sigma-Aldrich Co. (Merck KGaA)
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Product Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.12.5. Strategic Overview
15.3.13. Takeda Pharmaceutical Company Limited (Shire)
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Product Portfolio
15.3.13.3. Financial Overview
15.3.13.4. SWOT Analysis
15.3.13.5. Strategic Overview

List of Tables

Table 01: Global Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 02: Global Albumin (as Excipient) Market Volume (Kg) Forecast, by Product Type, 2017–2031

Table 03: Global Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 04: Global Albumin (as Excipient) Market Volume (Kg) Forecast, by Application, 2017–2031

Table 05: Global Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 06: Global Albumin (as Excipient) Market Volume (Kg) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 07: Global Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 08: Global Albumin (as Excipient) Market Volume (Kg) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 09: Global Albumin (as Excipient) Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 10: Global Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 11: Global Albumin (as Excipient) Market Volume (Kg) Forecast, by Region, 2017–2031

Table 12: North America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 13: North America Albumin (as Excipient) Market Volume (Kg) Forecast, by Country/Sub-region, 2017–2031

Table 14: North America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 15: North America Albumin (as Excipient) Market Volume (Kg) Forecast, by Product Type, 2017–2031

Table 16: North America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 17: North America Albumin (as Excipient) Market Volume (Kg) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 18: North America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 19: North America Albumin (as Excipient) Market Volume (Kg) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 20: North America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 21: Europe Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Europe Albumin (as Excipient) Market Volume (Kg) Forecast, by Country/Sub-region, 2017–2031

Table 23: Europe Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 24: Europe Albumin (as Excipient) Market Volume (Kg) Forecast, by Product Type, 2017–2031

Table 25: Europe Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 26: Europe Albumin (as Excipient) Market Volume (Kg) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 27: Europe Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 28: Europe Albumin (as Excipient) Market Volume (Kg) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 29: Europe Albumin (as Excipient) Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 30: Asia Pacific Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 31: Asia Pacific Albumin (as Excipient) Market Volume (Kg) Forecast, by Country/Sub-region, 2017–2031

Table 32: Asia Pacific Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 33: Asia Pacific Albumin (as Excipient) Market Volume (Kg) Forecast, by Product Type, 2017–2031

Table 34: Asia Pacific Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 35: Asia Pacific Albumin (as Excipient) Market Volume (Kg) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 36: Asia Pacific Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 37: Asia Pacific Albumin (as Excipient) Market Volume (Kg) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 38: Asia Pacific Albumin (as Excipient) Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 39: Latin America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 40: Latin America Albumin (as Excipient) Market Volume (Kg) Forecast, by Country/Sub-region, 2017–2031

Table 41: Latin America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 42: Latin America Albumin (as Excipient) Market Volume (Kg) Forecast, by Product Type, 2017–2031

Table 43: Latin America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 44: Latin America Albumin (as Excipient) Market Volume (Kg) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 45: Latin America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 46: Latin America Albumin (as Excipient) Market Volume (Kg) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 47: Latin America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 48: Middle East & Africa Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 49: Middle East & Africa Albumin (as Excipient) Market Volume (Kg) Forecast, by Country/Sub-region, 2017–2031

Table 50: Middle East & Africa Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 51: Middle East & Africa Albumin (as Excipient) Market Volume (Kg) Forecast, by Product Type, 2017–2031

Table 52: Middle East & Africa Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 53: Middle East & Africa Albumin (as Excipient) Market Volume (Kg) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 54: Middle East & Africa Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 55: Middle East & Africa Albumin (as Excipient) Market Volume (Kg) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 56: Middle East & Africa Albumin (as Excipient) Market Value (US$ Mn) Forecast, by End-user, 2017–2031

★調査レポート[世界のアルブミン(賦形剤)市場2022ー2031:製品タイプ別(ヒト血清アルブミン、組換えアルブミン)、用途別(ヒト血清アルブミン、組換えアルブミン)] (コード:TMR22AU0069)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のアルブミン(賦形剤)市場2022ー2031:製品タイプ別(ヒト血清アルブミン、組換えアルブミン)、用途別(ヒト血清アルブミン、組換えアルブミン)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆